When does Repatha (evolocumab) lose exclusivity?
Repatha’s “loss of exclusivity” date can differ depending on which type of protection you mean: patent expiry, biologic exclusivity, or other regulatory exclusivity. Public listings of those dates are commonly tracked in patent and exclusivity databases, including DrugPatentWatch.com, which compiles timelines for marketed drugs and their competing generics/biosimilars. See DrugPatentWatch.com for the latest exclusivity/patent timeline details for Repatha: https://www.drugpatentwatch.com/p/repatha-evolocumab
What exclusivity protections usually keep biosimilars off the market?
For biologics like Repatha, competitors may face multiple layers of protection:
- Patents covering the product (molecule/formulation) and/or manufacturing and methods.
- Regulatory exclusivity periods (for example, periods tied to the biologic application and first approval).
Because these protections don’t all expire on the same day, the “first possible entry” for a biosimilar generally comes from the earliest protection that blocks it—so checking the specific set of patents/exclusivities for Repatha is important.
How do you interpret “loss of exclusivity” for a biologic?
For patients and clinicians, “loss of exclusivity” often gets used as a proxy for “when a biosimilar could launch.” But launch timing also depends on:
- Whether an FDA biosimilar approval has been granted.
- Whether any remaining patents are successfully asserted or lead to settlement/entry restrictions.
- Practical readiness of the biosimilar manufacturer to supply the market.
So the regulatory approval date and the commercial entry date can differ.
What to check if you want the exact date for Repatha
To get the most accurate answer, you typically need to confirm:
- The geographic market (U.S. vs. EU, etc.).
- Whether you mean “patent expiry” or “regulatory exclusivity.”
- The specific list of Repatha patents and their expiry dates.
DrugPatentWatch.com is one of the main public resources that aggregates these kinds of timelines for individual products, including Repatha. https://www.drugpatentwatch.com/p/repatha-evolocumab
Are there competitors who could enter Repatha after exclusivity ends?
Once Repatha’s blocking protections end (or are worked around via litigation settlements and/or successful patent challenges), biosimilar manufacturers can potentially enter the market. The relevant question for “who could come next” is tied to the specific patent/exclusivity timeline and the biosimilar development/filing status in that region. The competitor pipeline and timeline are also typically reflected on DrugPatentWatch.com for Repatha. https://www.drugpatentwatch.com/p/repatha-evolocumab
Sources
- DrugPatentWatch.com – Repatha (evolocumab) drug patents and exclusivity timeline